The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Amphotericin B sodium desoxycholate     sodium; (1R,3S,5R,6R,9R,11R,15S,16R,17 R...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Amphotericin B sodium desoxycholate

  • The groups with invasive pulmonary aspergillosis studied consisted of UCs; rabbits treated with DAMB; rabbits treated with liposomal amphotericin B (LAMB) at 5 mg/kg/day; and rabbits treated with micafungin at 0.5, 1, and 2 mg/kg/day [1].
  • The groups with disseminated candidiasis studied consisted of untreated controls (UCs); rabbits treated with desoxycholate amphotericin B (DAMB) at 1 mg/kg of body weight/day; or rabbits treated with micafungin at 0.25, 0.5, 1, and 2 mg/kg/day intravenously [1].
  • In a prospective, comparative trial, treatment of co-infected cases with a pentavalent antimonial was found to have similar efficacy and toxicity to treatment with free ABD [2].

High impact information on Amphotericin B sodium desoxycholate


Biological context of Amphotericin B sodium desoxycholate


Anatomical context of Amphotericin B sodium desoxycholate


Associations of Amphotericin B sodium desoxycholate with other chemical compounds


Gene context of Amphotericin B sodium desoxycholate

  • The amphotericin B-deoxycholate (AB-DOC) system (1:2, mole basis) was studied with regard to its organizational properties making use of spin label ESR spectra [13].


  1. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Petraitis, V., Petraitiene, R., Groll, A.H., Roussillon, K., Hemmings, M., Lyman, C.A., Sein, T., Bacher, J., Bekersky, I., Walsh, T.J. Antimicrob. Agents Chemother. (2002) [Pubmed]
  2. Treatment of leishmaniasis in HIV-positive patients. Laguna, F. Ann. Trop. Med. Parasitol. (2003) [Pubmed]
  3. Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits. Walsh, T.J., Jackson, A.J., Lee, J.W., Amantea, M., Sein, T., Bacher, J., Zech, L. Antimicrob. Agents Chemother. (2000) [Pubmed]
  4. Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats. Echevarría, I., Barturen, C., Renedo, M.J., Trocóniz, I.F., Dios-Viéitez, M.C. Antimicrob. Agents Chemother. (2000) [Pubmed]
  5. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Collette, N., van der Auwera, P., Lopez, A.P., Heymans, C., Meunier, F. Antimicrob. Agents Chemother. (1989) [Pubmed]
  6. Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774. Chéron, M., Petit, C., Bolard, J., Gaboriau, F. J. Antimicrob. Chemother. (2003) [Pubmed]
  7. In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes. Pallister, C.J., Johnson, E.M., Warnock, D.W., Elliot, P.J., Reeves, D.F. J. Antimicrob. Chemother. (1992) [Pubmed]
  8. In-vitro effects of cilofungin (LY121019), amphotericin B and amphotericin B-deoxycholate on human polymorphonuclear leucocytes. Van der Auwera, P., Meunier, F. J. Antimicrob. Chemother. (1989) [Pubmed]
  9. Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity. Sabra, R., Zeinoun, N., Sharaf, L.H., Ghali, R., Beshara, G., Serhal, H. Pharmacol. Toxicol. (2001) [Pubmed]
  10. The effect of amphotericin B-deoxycholate on proliferation and protein synthesis in human skin fibroblast cultures. Fujimoto, W.Y., Starman, B.J., Rowe, D.W. In vitro. (1978) [Pubmed]
  11. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Fielding, R.M., Singer, A.W., Wang, L.H., Babbar, S., Guo, L.S. Antimicrob. Agents Chemother. (1992) [Pubmed]
  12. Animal models: usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis. Andriole, V.T., Miniter, P., George, D., Kordick, D., Patterson, T.F. Clin. Infect. Dis. (1992) [Pubmed]
  13. Polydispersity of aggregates formed by the polyene antibiotic amphotericin B and deoxycholate. A spin label study. Lamy-Freund, M.T., Ferreira, V.F., Schreier, S. Biochim. Biophys. Acta (1989) [Pubmed]
WikiGenes - Universities